Abstract:T he concept of cardiovascular risk factor is spontaneously, intuitively, associated with the notion of legacy, because individuals presenting high levels of risk factors will not suffer immediately from this situation. For example, in the pooled analyses of several trials of antihypertensive drugs against placebo or no treatment in mild-to-moderate hypertension [1], stroke incidence was less than 4% at 5 years in the control groups (Fig. 1). Three periods do exist in the disease process: complete latency, symptomatic phase, and cardiovascular complications phase. The symptomatic phase does not exist with cholesterol levels, whereas type 2 diabetes and hypertension are possibly associated with symptoms such as polyuria and polydipsia for the former and headaches for the latter. The duration of the first two phases is highly variable from an individual to another, but the evolution of arterial disease can spread over several years or tens of years, before the occurrence of symptoms of complications. A logical hypothesis comes naturally to mind that the duration of the exposure to high levels of risk factors has per se a prognostic value, the severity of the disease and of the complications being attributed to the legacy from this exposure. We can also view legacy in negative terms regarding treatment exposure when treatment successfully decreases the risk associated with the risk factor: the legacy of treatment consists in a decreased probability of complications extending beyond the period of the exposure to treatment. If the concept of legacy, regarding risk factor or its treatment, correctly captures the reality, physicians should consider it, screening the risk factors and treating them as early as possible. Prolonging treatment exposure as much as possible is usually associated with this reasoning, because the concept of lifelong treatment of risk factors prevails. This conclusion contradicts the current guidelines toward cardiovascular prevention, which base therapeutic decision on risk level through scores that integrates several risk factors rather than on the level of the risk factor targeted by the drug treatment. As age is by far the strongest risk factor, guidelines promote a late treatment initiation, leaving people exposed to a high level of risk factors. The risk is low during this abstention period, but under the legacy theory, the unopposed exposure to high risk factor levels would represent an accumulation of risk for subsequent periods. Of note, legacy effect is a very good concept for increasing the drug market. In this issue of the Journal of Hypertension, Nelson et al. [2] explore to what extent the past exposure to antihypertensive treatment of individuals without cardiovascular history and recruited in the second Australian National Blood Pressure Study was associated with a difference of prognosis. Although they expected that legacy (of unopposed hypertension or of treatment exposure) would lead to a better prognosis in those previously treated, they did not observe any difference in cardiovascular mortality at 10 years. On the contrary, previous treatment was associated during the trial with higher cardiovascular disease, all-cause mortality rate, and incidence of new-onset diabetes. This clearly contradicts the expectations from a legacy effect and supports the strategy of delaying the start of drug treatment in young hypertensive individuals whose risk within 5 or 10 years is low. Considering as a risk factor per se, the duration of the exposure to a risk factor raises the issue of the precise date at which the risk factor was elevated through life. Prescription habits bias the answer to this question: once the high level of risk factor is diagnosed and a drug treatment is started, the latter is exceptionally interrupted by prescribers, who usually consider that treatment is responsible for the good control of the risk factor. Given the large withinindividual variability of risk factors levels, the individuals with false-negative diagnoses of hypertension are submitted to lifelong treatment, without leaving a chance to patients to check whether the treatment is appropriate. This statement concerns blood pressure, glycemia, or cholesterol. A simple simulation illustrates that after 10 medical visits with blood pressure measurements, the individuals presenting the definition criteria of hypertension will include 30% of false positive, or an individual with systolic blood pressure of 130 mmHg will have 64% probability to be misdiagnosed as hypertensive [3]. Journal of Hypertension 2015, 33:2207–2209

Is legacy a myth or a reality? We should know, and we do not.

The comparative analysis of Lonicerae Japonicae Flos and Lonicerae Flos: A systematical review

Systematic review of Lonicerae Japonicae Flos: A significant food and traditional Chinese medicine

Lonicerae Japonicae Flos with the homology of medicine and food: a review of active ingredients, anticancer mechanisms, pharmacokinetics, quality control, toxicity and applications

Lonicera japonica Thunb.: Ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine

Lonicera Japonica Thunb. and Its Characteristic Component Chlorogenic Acid Alleviated Experimental Colitis by Promoting Lactobacillus and Fecal Short‐chain Fatty Acids Production

A comparative study of Lonicera japonica with related species: Morphological characteristics, ITS sequences and active compounds

Spectrum-Effect Relationships Between Chemical Fingerprints and Antibacterial Effects of Lonicerae Japonicae Flos and Lonicerae Flos Base on UPLC and Microcalorimetry

Comparative study on chemical constituents of different medicinal parts of Lonicera japonica Thunb. Based on LC-MS combined with multivariate statistical analysis

Comparison of the Anti-Inflammatory Active Constituents and Hepatotoxic Pyrrolizidine Alkaloids in Two Senecio Plants and Their Preparations by LC–UV and LC–MS

A Review: The Triterpenoid Saponins and Biological Activities ofLonicera Linn.

Biological Activities of Extracts from Loquat (eriobotrya Japonica Lindl.): A Review

Dissection of the potential anti-influenza materials and mechanism of Lonicerae japonicae flos based on in vivo substances profiling and network pharmacology

The phytochemistry, pharmacology, pharmacokinetics, quality control, and toxicity of Forsythiae Fructus: An updated systematic review

Updated pharmacological effects of Lonicerae japonicae flos, with a focus on its potential efficacy on coronavirus disease–2019 (COVID-19)

Anti-inflammatory property and functional substances of Lonicerae Japonicae Caulis

Study on phenolic acids of Lonicerae japonicae Flos based on ultra high performance liquid chromatography‐tandem mass spectrometry combined with multivariate statistical analysis

Pharmacokinetic Comparison of Eight Major Compounds of <i>Lonicerae japonicae flos</i> after Oral Administration in Normal Rats and Rats with Liver Injury

Cerclage cable in fracture: frustration or necessity?

Network Pharmacology-Based Identification of Potential Targets of Lonicerae japonicae Flos Acting on Anti-Inflammatory Effects